Drug Landscape ›
LUTETIUM CHLORIDE LU-177 ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 99
Most-reported reactions
Diarrhoea — 14 reports (14.14%) Anaemia — 12 reports (12.12%) Fatigue — 10 reports (10.1%) Nausea — 10 reports (10.1%) Nephropathy Toxic — 10 reports (10.1%) Pain In Extremity — 9 reports (9.09%) Thrombocytopenia — 9 reports (9.09%) Vomiting — 9 reports (9.09%) Abdominal Pain — 8 reports (8.08%) Cough — 8 reports (8.08%)
Source database →
LUTETIUM CHLORIDE LU-177 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is LUTETIUM CHLORIDE LU-177 approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for LUTETIUM CHLORIDE LU-177 in United States?
Marketing authorisation holder not available in our data.